Drug Trial Radar · NCT05145010
Extension Study of Infigratinib in Children With Achondroplasia (ACH)
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
325
Planned (sponsor's estimate)
Start
Dec 6, 2021
Primary completion
Dec 1, 2031
Study completion Feb 1, 2032
Sponsor
- Lead sponsor
- QED Therapeutics, a BridgeBio companyIndustry
- Sponsor type
- Industry
- First posted
- Dec 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, multicenter, open-label, extension (OLE) study to evaluate the long-term safety, tolerability, and efficacy of infigratinib, an FGFR 1-3-selective tyrosine kinase inhibitor, in participants with ACH who previously completed a QED-sponsored interventional study, and in additional participants who are naïve to infigratinib treatment. Quality of Life assessments for this participant population will also be evaluated. Treatment-naïve participants must have at least a 6-month period of growth assessment in study QBGJ398-001 (PROPEL) and will be enrolled in this OLE study if the sponsor deems additional long-term safety and/or efficacy data are necessary, and participants are not otherwise eligible to enroll in another QED-sponsored Phase 2 or Phase 3 ACH study.
Conditions
- Achondroplasia
Interventions
InfigratinibDrug
Infigratinib minitablets or sprinkle capsules to be administered by mouth. In participants that completed a prior study with infigratinib, the starting dose will be the same as the last dose received in the prior interventional study with infigratinib. Infigratinib dose may be adjusted to 0.25 mg/kg/day.
InfigratinibDrug
Infigratinib sprinkle capsules to be administered by mouth. Starting dose for the participants naïve to Infigratinib will be 0.25 mg/kg/day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment emergent adverse events (TEAE) and serious TEAETime frame: 10 years
- Changes over time in height Z-score in relation to ACH and general pediatric population tablesTime frame: 10 years
Locations
31 sites in 10 countries. Site status is shown where the registry gives one.
UCSF Benioff Children's Hospital, Oakland
Oakland, California
Children's Hospital Colorado
Aurora, Colorado
Nemours Alfred I. Dupont Hospital for Children
Wilmington, Delaware
Johns Hopkins University
Baltimore, Maryland
University of Missouri
Columbia, Missouri
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Vanderbilt University Medical Center
Nashville, Tennessee
University Hospital and UW Health Clinics
Madison, Wisconsin
Hospital de Pediatría SAMIC Prof. Dr. Juan P. Garrahan
Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina
Murdoch Children's Hospital
Parkville, Victoria, Australia
Stollery Children's Hospital
Edmonton, Alberta, Canada
Children's Hospital - London Health Sciences Centre
London, Ontario, Canada
Children's Hospital of Eastern Ontario
Ottawa, Ontario, Canada
Centre Hospitalier Universitaire Sainte-Justine
Montreal, Quebec, Canada
Hopital Femme Mere Enfant
Lyon, France
Hopital Necker-Enfants Malades
Paris, France
Hopital des Enfants
Toulouse, France
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
Policlinico A. Gemelli IRCCS
Roma, Italy
Haukeland University Hospital
Bergen, Norway
Oslo University Hospital
Oslo, Norway
KK Women's and Children's Hospital
Singapore, Singapore
Hospital Universitario La Paz
Madrid, Spain
Hospital Universitario Virgen de la Victoria
Málaga, Spain
Hospital Vithas San José
Vitoria-Gasteiz, Álava, Spain
Birmingham Women's and Children's NHS Foundation Trust
Birmingham, United Kingdom
University Hospitals Bristol and Weston NHS Foundation Trust
Bristol, United Kingdom
Queen Elizabeth University Hospital
Glasgow, United Kingdom
St. Thomas' Hospital
London, United Kingdom
Manchester University Children's Hospital
Manchester, United Kingdom
Sheffield Children's Hospital
Sheffield, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.